Elekta’s Q2 results (particularly profitability) came in ahead of market expectations. While margin pressure has continued, the sales growth and order-book progression have remained encouraging. As oncology markets continue to recover and the promising market potential remains intact, the likes of Elekta remain in a sweet spot. Although, near-term profitability challenges are likely to persist and re-emerging COVID-19 risks could be another sentiment dampener.
